Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States

By sjmartinez • April 11, 2025

Luo Y, Assassi S, Mayes MD, Frech TM, Steen VD, Richardson C, Chung L, Sandorfi N, VanBuren JM, Harding M, Alvey JS, Skaug B, McMahan Z, Lakin KS, Zahn C, Bracken SJ, Lebiedz-Odrobina DJ, Molitor JA, Evnin LB, Moore DF, Shah A, Castelino FV, Volkmann ER, Hant FN, Makol A, Shah AA, Hummers LK, Gordon JK, Khanna D, Bernstein EJ. Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States. Ann Am Thorac Soc. 2025 Apr 10. doi: 10.1513/AnnalsATS.202410-1045RL. Epub ahead of print. PMID: 40208257.

Tags: Publications, Rheumatology

Related Posts

Sleep apnea in individuals with spinal cord injury

Sankari A, Aldwaikat A, Habra M, Salloum A, Zeineddine S, Pandya N, Martin JL, Badr MS. Sleep apnea in individuals with spinal cord injury. J[...]

Abstracts of the 26th International Workshop on Clinical Pharmacology of HIV, Hepatitis and other Antiviral Drugs 2025, 3-4 September 2025, Amsterdam, the Netherlands

Nerguizian D, Wei Z, Aldrovandi G, Currier J, Eron J, Fischer W, Gandhi R, Hamill M, Hosey L, Javan A, McCarthy C, Nachman S, Valiyaparambil[...]

Efficacy and safety of bridging intravenous thrombolysis before mechanical thrombectomy: A systematic review and meta-analysis

Hashmi TM, Ahmed M, Ashraf H, Shakir M, Bhatti IA, Alareed A, Ahmed F, Hasan A, Ahmed R, Aized MT, Rafiq S, Fonarow GC, Hassan[...]